ASCO 2026: First to first line in HER-2 NSCLC, with Itziar Canamasas

Boehringer Ingelheim is continuing to see success with zongertinib (Hernexeos) in HER-2 positive non-small cell lung cancer as well as in other indications. At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum Editor in Chief Jonah Comstock about the company's ASCO data, which shows improvements in both efficacy and tolerability.

Canamasas also discusses how the company’s most recent data fits into the larger oncology strategy at BI, and talks about the challenges of extending a drug across new indications.

The interview also covers precision medicine and some of the access challenges it presents. Finally, Canamasas shares a little bit about how BI is using AI, and the trends she’s seeing at the show.

Check out the interview below. This video is intended for US audiences.